Arvinas advances new oral immunotherapy into Phase 1 clinical trial
Arvinas announced that the first participant has been dosed in its Phase 1/2 clinical trial of ARV-6723, an investigational oral PROTAC designed to degrade hematopoietic progenitor kinase 1 in adults with advanced solid tumors. The ARV-6723-101 trial is a global, multicenter, first-in-human study de
<p>Arvinas announced that the first participant has been dosed in its Phase 1/2 clinical trial of ARV-6723, an investigational oral PROTAC designed to degrade hematopoietic progenitor kinase 1 in adults with advanced solid tumors. The ARV-6723-101 trial is a global, multicenter, first-in-human study de</p>